This is a research study that will test a new remote monitoring technology to assess smoking in the natural environment among adolescents and young adults ages 15-25. After assessment and inclusion in the study, participants will be asked to report on their smoking by answering questions on a mobile phone for 35 days. Participants will also be asked to make a brief quit attempt lasting for approximately 48 hours. There is no cost to participate and compensation is available to those who qualify.
Smoking cessation is the most important strategy available to reduce lung cancer risk. To date, there has been no research on tobacco cessation in lung screening patients, who may have unique attributes (e.g., anxiety about having a nodule coupled with tobacco dependence). We thus propose to evaluate 2 novel behavioral interventions as adjuncts to standard pharmacotherapy. We will enroll and randomize 276 patients undergoing lung screening to Intervention 1 (gain-framed personalized video and print intervention). We will evaluate whether this will improve tobacco quit rates above and beyond standard of care smoking cessation treatment over 8 weeks. Then we will perform a second randomization to Intervention 2, an individual-level, biofeedback intervention. We will then evaluate whether this intervention will reduce smoking rates at 6 months.
This research is a randomized smoking cessation trial conducted within and specifically personalized for lung cancer screening patients presenting to a lung screening clinic. Novel tobacco treatments for this population are critically needed, given the growing population of lung screening patients. In the proposed study, we will test a gain-framed messaging intervention specifically designed for lung screening patients (vs. unframed messaging), as well as evaluating NRT sampling (vs. no medication).
The study will compare two sets of professionally-recommended guidelines for follow-up of patients with small lung nodules. The two guidelines are different in the frequency and timing of follow-up; one is more frequent and the one is less frequent. All patients who have a small lung nodule detected on a chest scan will have a recommended follow-up schedule automatically inserted into their imaging report so that their health care provider may follow the guideline-recommended intervals for follow-up chest scans. Patients and their physicians may choose not to follow the recommendations, depending on preference or the physician's clinical judgment. As part of this research study, information from patients with a small lung nodule who are seen at MUSC will be collected from the electronic medical record. This will include characteristics of the patient (such as age, smoking history), basic information about the lung nodule (such as nodule size, nodule density), and the medical care received.
The purpose of this study is to assess the effects of N-Acetylcysteine (NAC), an over-the-counter antioxidant, to assist adult cigarette smokers with quitting and preventing relapse to smoking. This medication may help people quit smoking by reducing withdrawal symptoms, craving, and preventing relapse, but we do not know if NAC helps smokers early in their quit attempt or after they have already quit.
This study is investigating the effects of combining 2 medications, Varenicline (commonly known as Chantix®) and N-acetylcysteine, on smoking behavior in daily cigarette smokers who are interested in quitting smoking. The study consists of 10 visits over 6 weeks. Compensation is available for those that qualify. Smokers must be between the ages of 18 and 55.
CREST-2 is two parallel multi-center randomized, observer-blinded endpoint clinical trials. One trial will assess treatment differences between intensive medical management alone compared to carotid endarterectomy procedure plus intensive medical management. The parallel trial will assess treatment differences between intensive medical management alone compared to carotid artery stenting plus intensive medical management. Intensive medical management will involve control of blood pressure, LDL cholesterol, cigarette smoking, and other vascular risk factors.
The goal of this study is to determine whether transcranial magnetic stimulation (TMS) is an effective treatment in decreasing craving in individuals who habitually smoke cigarettes. The study consists of six total visits to MUSC; one for the consent process, two that will include MRI scans, and five that will include TMS administration. Compensation will be provided for each visit.
Nicotine dependence remains a significant public health concern. Nicotine can affect brain neural oscillations. A magnetic field applied to the outside of the skull can produce electrical activity in the brain without significant pain or the need for anesthesia. In this proposal, we will build an individual brain signal-driven transcranial magnetic stimulation loop, and then test whether this stimulation loop can modulate neural oscillations and reduce cue-induced craving, including nicotine craving. This research will build an innovative brain stimulation method for neuroscientific research and develop a potential efficacy therapy for nicotine dependence as well other neuropsychiatric disorders.
This research is being conducted at the Medical University of South Carolina Institute of Psychiatry Brain Stimulation Lab by Dr. Mark George to see if deep repetitive transcranial magnetic stimulation (dTMS) is effective in assisting participants to quit smoking. TMS is a noninvasive medical procedure that uses magnetic fields to stimulate nerve cells in the brain to act as an aid to smoking cessation. The treatment period will involve 18 active/sham treatments to be given daily for 3 weeks then weekly treatments in week 4, 5, and 6. A follow up visit will be scheduled about 2 1/2 months after week 6. The entire study is four months in duration. Participants who may be recruited into the study would include the following: men and women 22-70 years of age, chronic; heavy smokers who have smoked for more than 1 year, with no period of abstinence greater than 3 months during the past year; subjects who are motivated to quit smoking; subjects who have negative answers on the TASS; and those who are able to sign an informed consent.